March 11, 2026. 20 cannabis research items from PubMed, sorted by clinical priority.
Evidence Watch | Nature medicine (2025)
Study Summary
This phase 3 trial evaluated full-spectrum cannabis extract for chronic low back pain treatment, addressing a condition affecting over 500 million people globally where current pharmacotherapies demonstrate limited efficacy and significant safety concerns.
Evidence Watch | Acta paediatrica (Oslo, Norway : 1992) (2025)
Cannabinoids for Medical Purposes in Children: A Living Systematic Review.
Study Summary
This living systematic review continuously evaluates safety and efficacy data of cannabinoids for pediatric medical use, enabling clinicians to access updated evidence on cannabinoid treatment outcomes in children.
Evidence Watch | British journal of sports medicine (2026)
Study Summary for Cannabis Clinicians
This systematic review identifies mental health symptoms and influencing factors in retired high contact team sport athletes, potentially informing cannabis treatment considerations for this population’s psychiatric outcomes.
Evidence Watch | Journal of medical Internet research (2024)
Study Finding Summary
The Minder mobile intervention showed effectiveness for university students’ mental health and substance use challenges, offering cannabis clinicians a scalable digital tool model for student populations during vulnerable transition periods.
Evidence Watch | Journal of anxiety disorders (2024)
This meta-analysis examines whether evidence-based PTSD treatments remain effective for individuals with co-occurring cannabis use and substance use disorders, directly informing clinical treatment decisions.
Evidence Watch | BMJ open (2026)
REAL 2.0 Study Summary for Cannabis Clinicians
The abstract provided is incomplete and contains no findings. A one-sentence summary cannot be written without access to the study’s results section or conclusions.
Evidence Watch | Annals of the rheumatic diseases (2026)
Study Summary
**Unable to provide findings summary:** The abstract provided is incomplete and cuts off before results are presented, preventing accurate characterization of study outcomes for clinical relevance.
Evidence Watch | International journal of environmental research and public health (2026)
Study Summary
Cannabis flower use showed greater daily anxiety reduction than edibles, suggesting product type influences therapeutic efficacy for anxiety management in clinical populations.
Evidence Watch | Journal of sleep research (2026)
Study Summary
This pilot trial examined how oral cannabinoids (THC and CBD) affect sleep architecture and daytime function using high-density EEG, providing clinicians evidence-based data on cannabinoid efficacy for insomnia treatment.
Evidence Watch | Clinical pharmacology and therapeutics (2026)
CBD showed no direct effect on cortical excitability in this randomized controlled trial, suggesting its anti-seizure benefits in Dravet and Lennox-Gastaut syndromes may operate through mechanisms other than direct cortical modulation.
Evidence Watch | Journal of psychiatric research (2025)
Study Finding Summary
Pre-trauma insomnia predicted increased posttraumatic cannabis use in trauma survivors, suggesting clinicians should assess insomnia when treating cannabis use disorder in this population.
Evidence Watch | JAMA health forum (2026)
Adolescent Cannabis Use and Risk of Psychotic, Bipolar, Depressive, and Anxiety Disorders.
Study Finding Summary
Adolescent cannabis use is associated with increased risk of psychotic, bipolar, depressive, and anxiety disorders, requiring clinicians to assess cannabis exposure during mental health evaluations in youth populations.
Evidence Watch | Drug and alcohol dependence (2016)
Study Summary
Adolescents with internalising symptoms (depression, anxiety) may use cannabis as self-medication; clinicians should screen for and address underlying mental health conditions when treating cannabis use in this population.
Evidence Watch | Journal of clinical pharmacology (2025)
Study Summary
This systematic review evaluates cannabis derivatives and analogs as potential therapeutic interventions for autism spectrum disorder, assessing clinical evidence for their efficacy in managing autism-related symptoms.
Evidence Watch | The Journal of clinical psychiatry (2024)
Study Finding Summary
Maternal cannabis use during pregnancy is associated with increased risk of autism spectrum disorder or ADHD in offspring, relevant to clinicians counseling pregnant patients on cannabis safety.
Evidence Watch | Addictive behaviors (2026)
Working memory capacity predicts cannabis-induced effects on alcohol urge.
Study Summary for Cannabis Clinicians
Working memory capacity predicts individual differences in cannabis’s effects on alcohol craving, suggesting cognitive capacity may help identify patients at risk for altered alcohol use patterns when using cannabis.
Evidence Watch | Cannabis and cannabinoid research (2026)
Study Summary
This trial evaluates whether topical cannabis balms can effectively treat musculoskeletal pain in postmenopausal breast cancer patients using aromatase inhibitors, addressing a common treatment side effect affecting two-thirds of this population.
Evidence Watch | Psychiatry research. Neuroimaging (2026)
Study Finding Summary
A single CBD dose modulated the relationship between hippocampal glutamate and prefrontal brain activation during learning tasks in individuals at clinical high risk for psychosis, suggesting a potential neurobiological mechanism relevant to psychosis prevention.
Evidence Watch | Medicine and science in sports and exercise (2026)
Study Finding Summary
Broad-spectrum CBD supplements contain prohibited cannabinoids that accumulate in urine with daily use and exercise, potentially causing positive WADA drug tests despite CBD’s legal status.
Evidence Watch | Journal of neurodevelopmental disorders (2025)
Study Summary
ZYN002, a transdermal cannabidiol gel, demonstrated long-term safety and tolerability in pediatric FXS patients, providing clinical evidence for cannabidiol’s potential therapeutic application in this genetic disorder characterized by dysregulated endocannabinoid signaling.
Clinical Commentary
Clinical Reflection
These studies collectively demonstrate that cannabis medicine is transitioning from symptomatic relief toward mechanism-based, population-specific application, with particular promise in pain syndromes and anxiety disorders while flagging significant safety concerns in vulnerable populations including adolescents, pregnant women, and those with underlying psychiatric vulnerability. The evidence increasingly suggests that cannabinoid formulation type (flower vs. edible), cannabinoid ratio (THC:CBD balance), and individual risk stratification are as clinically relevant as the compounds themselves, requiring more nuanced prescribing frameworks than current practice often reflects. My responsibility as a cannabis-knowledgeable physician is to move beyond permissive attitudes toward therapeutic use and instead adopt the same rigorous risk-benefit analysis I apply to other medications, particularly regarding developmental windows and psychiatric comorbidities where the data signal real harm.
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
